Confidential Materials omitted and filed separately with the Securities and Exchange Commission. [****] denotes omissions. THIRD AMENDMENT TO DISCOVERY AND DEVELOPMENT COLLABORATION AND LICENSE AGREEMENTDiscovery and Development Collaboration and License Agreement • February 24th, 2015 • Agios Pharmaceuticals Inc • Pharmaceutical preparations
This Third Amendment to the Discovery and Development Collaboration and License Agreement (the “Third Amendment”) is entered into as of July 14th, 2014 (the “Third Amendment Effective Date”) by and between Agios Pharmaceuticals, Inc. (“Agios”) and Celgene Corporation (“Celgene”). Agios and Celgene may each be referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used in this Third Amendment and not otherwise defined herein shall have the meanings set forth in the Agreement. All references to Sections and Articles herein are references to Sections and Articles of the Agreement.
